

Supporting Information

Preparation, *in vitro* and *in vivo* evaluation, and molecular dynamics (MD) simulation studies of novel F-18 labeled tumor imaging agents targeting focal adhesion kinase (FAK)

Yu Fang^{a,b}, Dawei Wang^a, Xingyu Xu^a, Gila Dava^a, Jianping Liu^a, Xiang Li^a, Qianqian Xue^a,
Huan Wang^a, Jiangshan Zhang^b, Huabei Zhang^{a,*}


^a Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China.

^b College of Chemistry and Chemical Engineering, Anyang Normal University, No. 436 Xian' ge Avenue, Anyang 455000, P. R. China


Corresponding Author:

For H. Zhang: phone +86-10-58802012, E-mail hbzhang@bnu.edu.cn.


¹H-NMR of **5**:



¹H-NMR of 7a:



¹³C-NMR of **7a**:




ESI-MS of **7a**:


ESI-MS Spectrum, XXY-1-2


#1 Ret. Time: Averaged 1.227-1.680(Scan#:47-64)

Base Peak: 630.90(273052) Polarity: Pos Segment1 - Event1
Intensity




¹H-NMR of 7b:




^{13}C -NMR of **7b**:


ESI-MS of **7b**:




¹H-NMR of [¹⁹F]2



^{13}C -NMR of $[^{19}\text{F}]\text{2}$



¹⁹F-NMR of [19F]2



```


NAME      XXY-1-2-F
EXPNO     1
PROCNO    1
Date_     20171106
Time      10.50
INSTRUM    spect
PROBHD     5 mm PABBO BB/
PULPROG    zgpg30
TD         131072
SOLVENT    CDCl3
NS         2
DS         4
SFO1       15000.000 MHz
FIDRES     0.114441 Hz
AQ         4.3551160 sec
RG         201.95
DM         22.222 usec
DE         6.50 usec
TE         298.2 K
D1         1.00000000 sec
D11        0.03000000 sec
D12        0.00002000 sec
TDO        1
===== CHANNEL f1 =====
SFO1       376.463260 MHz
NUC1       19F
P1         13.07 usec
SI         65536
SF         376.463260 MHz
WDW         EM
SSB         0
LB         0.30 Hz
GB         0
PC         1.00
    
```

ESI-MS of [¹⁹F]2


ESI-MS Spectrum, XXY-1-2-F

#1 Ret.Time:Averaged 1.333-1.547(Scan#:51-59)


Base Peak: 477.10(227996) Polarity:Pos Segment1 - Event1




¹H-NMR of [¹⁹F]3



^{13}C -NMR of $[\text{F}^{19}]\text{3}$




¹⁹F-NMR of [¹⁹F]3




```

NAME      XXY-1-3-F
EXPNO     1
PROCNO    1
Date_     20171106
Time      10.50
INSTRUM    spect
PROBHD     5 mm PABBO BB/
PULPROG    zgpg30pm
TD         131072
SOLVENT    CDCl3
NS         7
DS         4
SFO1       15000.000 MHz
FIDRES     0.114441 MHz
AQ         4.3051160 sec
RG         201.95
DM         22.222 usec
DE         6.50 usec
TE         298.5 K
D1         1.00000000 sec
D11        0.03000000 sec
D12        0.00002000 sec
TDO        1
===== CHANNEL f1 =====
SFO1       376.4126526 MHz
NUC1        19F
P1         13.07 usec
SI         65526
SF         376.4503260 MHz
WDW         EM
SSB         0
LB         0.30 MHz
GB         0
PC         1.00
    
```


ESI-MS of [^{19}F]**3**




^1H -NMR of $[\text{}^{19}\text{F}]\mathbf{0}$ (including the chemical structure of $[\text{}^{19}\text{F}]\mathbf{1}$) ^a



the chemical structure of $[\text{}^{18}\text{F}]\mathbf{1}$



¹³C-NMR of [¹⁹F]1 a




ESI-MS of [¹⁹F]1 ^a

ESI-MS Spectrum, XXY-1-I-F

#1 Ret.Time:Averaged 2.373-3.093(Scan#:90-117)

Base Peak: 435.2 (159179) Polarity:Pos Segment1 - Event1
Intensity



^a The chemical structure and the related spectrum of [¹⁹F]1, and the chemical structure of its corresponding F-18 labeled radiotracer [¹⁸F]1, were cited from our published work:

D. Wang, Y. Fang, H. Wang, X. Xu, J. Liu and H. Zhang, RSC Advance, 2017, 7, 22388-22399.

(Note: The [¹⁹F]1 in this work was named **8a** in the above published work, and its corresponding F-18 labeled radiotracer [¹⁸F]1 was named [¹⁸F]-**8a** in the above published work.)

Table S1Biodistribution in S180-tumor-bearing mice after intravenous injection of [¹⁸F]**1**^{a,b} (logP = 3.32±0.04)

Organs	Time (min)				
	5	15	30	60	120
Blood	6.62±0.25	4.73±0.82	2.19±0.01	1.93±0.10	0.81±0.01
Brain	1.20±0.12	0.89±0.18	1.19±0.18	1.51±0.12	0.83±0.14
Heart	1.23±0.15	2.44±0.22	2.45±0.46	1.97±0.29	1.61±0.20
Liver	3.29±0.02	1.99±0.23	1.75±0.32	1.57±0.30	0.50±0.06
Spleen	1.98±0.03	1.65±0.11	2.28±0.12	1.74±0.19	0.92±0.34
Lung	8.73±1.26	8.96±1.35	7.39±1.29	4.23±0.57	3.81±0.44
Kidney	0.70±0.09	1.62±0.23	4.58±0.44	6.39±0.79	7.37±0.64
Muscle	1.38±0.21	1.47±0.19	1.73±0.20	1.97±0.25	1.59±0.27
Bone	1.88±0.13	1.95±0.25	3.79±0.42	4.16±0.46	4.71±0.53
Intestine ^b	0.06±0.02	0.43±0.07	0.28±0.06	0.11±0.02	0.34±0.08
Stomach ^b	0.05±0.01	0.23±0.03	0.42±0.03	0.37±0.09	1.35±0.05
Tumor	3.39±0.25	3.69±0.51	3.71±0.43	3.23±0.14	3.11±0.22
Tumor/Muscle	2.46	2.51	2.14	1.64	1.96
Tumor/Bone	1.80	1.89	0.98	0.78	0.66
Tumor/Blood	0.55	0.78	1.69	1.67	3.84

^a The preparation and the related biological evaluation results of [¹⁹F]**1** and its corresponding F-18 labeled radiotracer [¹⁸F]**1**, were cited from our published work: D. Wang, Y. Fang, H. Wang, X. Xu, J. Liu and H. Zhang, RSC Advance, 2017, 7, 22388-22399.

(Note: The [¹⁹F]**1** in this work was named **8a** in the above published work, and its corresponding F-18 labeled radiotracer [¹⁸F]**1** was named [¹⁸F]-**8a** in the above published work. The chemical structures of [¹⁹F]**1** and [¹⁸F]**1** were shown in the *Supplementary Materials*.)

The *in vivo* biodistribution studies of [¹⁸F]**1** in S180-tumor-bearing mice, were performed in the same batch with the F-18 radiotracers in this work, and were cited from the above published work. What's more, we have checked some errors in the calculation of the logP and a few of biodistribution data of the [¹⁸F]**1** from our original experimental data. Therefore, we have made corrections in these tables and adjusted some discussions in the corresponding positions in the manuscript.

^b Expressed as % injected dose per gram (%ID/g) unless otherwise indicated. Data are the average for five mice ± standard deviation.

Table S2Biodistribution in S180-tumor-bearing mice after intravenous injection of [¹⁸F]**2**^{a,b,c} (logP = 2.97±0.10)

Organs	Time (min)					
	5	15	30	60	120	30 (blockade) ^c
Blood	6.17±0.36	4.36±0.62	3.08±0.26	3.24±0.25	2.31±0.18	2.86±0.31
Brain	2.52±0.44	1.70±0.13	2.32±0.31	2.05±0.32	1.83±0.32	1.96±0.20
Heart	2.37±0.15	2.81±0.09	2.93±0.14	2.88±0.23	2.61±0.25	2.48±0.08
Liver	3.52±0.49	3.36±0.56	2.59±0.20	2.36±0.46	1.73±0.25	2.89±0.52
Spleen	2.94±0.01	2.34±0.14	2.68±0.28	1.93±0.04	1.61±0.21	2.53±0.14
Lung	10.45±0.52	6.13±0.48	2.84±0.34	2.61±0.20	1.94±0.32	2.35±0.23
Kidney	5.67±0.12	5.62±0.27	5.95±0.11	6.12±0.12	6.73±0.11	5.83±0.68
Muscle	1.87±0.28	2.25±0.20	2.39±0.41	2.37±0.14	2.47±0.18	2.64±0.13

Bone	2.52±0.20	3.30±0.52	3.84±0.63	4.08±0.53	4.51±0.71	3.39±0.24
Intestine ^b	1.20±0.07	2.66±0.09	3.30±0.09	4.33±0.09	5.18±0.02	3.33±0.07
Stomach ^b	0.47±0.08	0.51±0.04	0.51±0.01	0.45±0.03	0.27±0.03	0.57±0.09
Tumor	3.59±0.36	4.11±0.62	5.96±0.09	4.07±0.50	3.86±0.14	0.72±0.05
Tumor/Muscle	2.86	2.40	2.49	1.72	1.56	/
Tumor/Bone	2.12	1.64	1.55	1.00	0.86	/
Tumor/Blood	0.58	0.94	1.94	1.26	1.67	/


^aExpressed as % injected dose per gram (%ID/g) unless otherwise indicated. Data are the average for five mice ± standard deviation. ^bExpressed as % injected dose per organ (%ID) . ^c Each animal received PF-562,271 (a dose of 33 mg/kg, p.o.) at one hour before the intravenous radiotracer injection (blocking study).

Table S3


Biodistribution in S180-tumor-bearing mice after intravenous injection of [¹⁸F]3 ^a (logP = 2.86±0.06)

Organs	Time (min)				
	5	15	30	60	120
Blood	6.48±0.92	4.19±0.33	2.41±0.15	2.35±0.22	2.13±0.14
Brain	2.54±0.11	2.43±0.07	1.91±0.10	2.50±0.12	2.57±0.07
Heart	2.48±0.18	1.61±0.24	1.26±0.09	1.63±0.09	1.86±0.13
Liver	4.14±0.12	4.65±0.28	3.74±0.11	2.24±0.16	1.85±0.04
Spleen	2.87±0.24	2.11±0.19	1.47±0.13	1.25±0.11	0.98±0.07
Lung	10.63±0.61	6.44±0.73	4.86±0.30	4.09±0.63	3.53±0.32
Kidney	2.07±0.16	3.49±0.12	4.39±0.07	5.89±0.48	6.50±0.91
Muscle	3.10±0.05	2.55±0.23	2.07±0.10	2.58±0.29	2.65±0.20
Bone	3.16±0.16	2.57±0.03	3.07±0.10	3.90±0.17	3.50±0.34
Intestine ^b	0.90±0.06	2.24±0.12	4.62±0.04	4.78±0.02	5.72±0.13
Stomach ^b	1.54±0.08	1.44±0.06	1.54±0.10	1.56±0.16	1.52±0.19
Tumor	3.08±0.20	2.80±0.33	3.24±0.07	2.97±0.47	2.88±0.44
Tumor/Muscle	0.99	1.10	1.57	1.54	1.46
Tumor/Bone	0.98	1.09	1.06	1.02	1.11
Tumor/Blood	0.47	0.67	1.34	1.26	1.35


^a Expressed as % injected dose per gram (%ID/g) unless otherwise indicated. Data are the average for five mice ± standard deviation. ^bExpressed as % injected dose per organ (%ID) .




[¹⁸F]2--normal saline, 37 °C, 1 h




[¹⁸F]2--normal saline, 37 °C, 2 h




[¹⁸F]2--murine plasma, 37 °C, 1 h




[¹⁸F]2--murine plasma, 37 °C, 2 h




[¹⁸F]3--normal saline, 37 °C, 1 h



[¹⁸F]3--normal saline, 37 °C, 2 h




[¹⁸F]**3**--murine plasma, 37 °C, 1 h




[¹⁸F]**3**--murine plasma, 37 °C, 2 h

Fig. S1. The HPLC chromatogram of F-18 labeled radiotracers in normal saline and murine plasma at 37 °C after 1 h and 2 h, respectively. The HPLC profile data were exported from the *.lcd files by Shimadzu LCSolution Software, and were graphically interpreted and coordinate translated by Origin 8.0.


The in vitro stability of [¹⁸F]**1** was shown in our published work: D. Wang, Y. Fang, H. Wang, X. Xu, J. Liu and H. Zhang, RSC Advance, 2017, 7, 22388-22399.



[¹⁹F]**1** in the FAK binding pocket



[¹⁹F]**2** in the FAK binding pocket



[¹⁹F]**3** in the FAK binding pocket

Fig. S2. The docking studies on the interaction of [¹⁹F]**1** [¹⁹F]**2** and [¹⁹F]**3** with the FAK. (Most of the residues in the binding pocket of the FAK were shown as “Lines”, while the key residue which have hydrogen-bonding interactions with the F-19 standards were shown as “Ball and Stick”, the F-19 standards were shown as “Capped Sticks”, and the hydrogen bonds were shown as “Yellow Dotted Line”).